Methods of use of emulsion formulations of an NK-1 receptor antagonist
Inventors
Ottoboni, Thomas B. • Han, Han
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Core Innovation
The disclosure relates to stable oil-in-water injectable emulsions of a neurokinin-1 (NK-1) receptor antagonist for parenteral treatment, including intravenous (IV) administration, for prevention and treatment of emesis. The emulsion includes an oil phase, a phospholipid emulsifier, a co-surfactant such as an alcohol, and an aqueous phase with tonicity/osmotic agents and pH modifiers. A formulation scope is provided that includes NK-1 receptor antagonists such as aprepitant and other NK-1 antagonists.
The problem addressed is emesis prevention and treatment by delivering an NK-1 receptor antagonist as an injectable pharmaceutical emulsion with physical stability, including minimizing formation of NK-1 antagonist crystals, creaming, and cracking. Stability targets and characterization criteria are stated, including USP <729> and droplet-size limitations, with observations intended to indicate the absence of visible drug crystals. The disclosure also includes assessment by dynamic light scattering (DLS) and zeta potential.
The formulation is further characterized by compositional ratio constraints, including an emulsifier-to-NK-1 receptor antagonist weight ratio ranging from about 18:1 to 22:1 (wt/wt%) for the claimed method. An optional additional drug content is described as dexamethasone sodium phosphate in the aqueous phase, and the disclosure includes example comparisons using pharmacokinetics data in rats, indicating faster and greater initial aprepitant exposure for the emulsion relative to a fosaprepitant solution.
Claims Coverage
The independent claim provides a method for preventing post-operative nausea and vomiting by administering an injectable pharmaceutical emulsion containing an NK-1 receptor antagonist, an emulsifier, an oil, a co-surfactant, and an aqueous phase, with a specific emulsifier-to-NK-1 receptor antagonist weight ratio. The inventive features are primarily defined by the required emulsion components and the emulsifier-to-antagonist ratio constraint, while dependent claims add further component selections and quantitative refinements.
Emulsion-based emesis prevention
A method for preventing post-operative nausea and vomiting in a subject by administering an injectable pharmaceutical emulsion comprising a neurokinin-1 (NK-1) receptor antagonist, an emulsifier, an oil, a co-surfactant, and an aqueous phase.
Emulsifier-to-NK-1 receptor antagonist wt/wt ratio
The ratio of the emulsifier to the NK-1 receptor antagonist ranges from about 18:1 to 22:1 (wt/wt%).
Aprepitant as the NK-1 receptor antagonist
The method is performed using aprepitant as an NK-1 receptor antagonist.
Oil-to-NK-1 receptor antagonist wt/wt ratio
The oil to NK-1 receptor antagonist ratio ranges from about 5:1 to 15:1 (wt/wt%).
Emulsifier loading wt/wt range
The emulsion includes an emulsifier at about 11 to 15 wt/wt%.
Dexamethasone sodium phosphate in aqueous phase
The emulsion includes dexamethasone sodium phosphate in the aqueous phase.
Ethanol content threshold
The emulsion contains ethanol at less than 10 wt/wt%.
Overall, the claims cover an injectable emulsion method for preventing post-operative nausea and vomiting in a subject using an NK-1 receptor antagonist in an oil-in-water emulsion with specified component requirements, anchored by an emulsifier-to-antagonist weight ratio of about 18:1 to 22:1 (wt/wt%). Dependent refinements specify particular NK-1 antagonists, additional ratio constraints for oil and emulsifier loading, an ethanol content threshold, and optional co-formulation with dexamethasone sodium phosphate in the aqueous phase.
Stated Advantages
Provides stability targets for an injectable oil-in-water emulsion, including minimizing creaming/cracking and minimizing formation of NK-1 antagonist crystals.
Provides droplet-size stability consistent with USP <729> and PFAT5 limits.
Indicates faster and greater initial aprepitant exposure for the emulsion relative to a fosaprepitant solution in pharmacokinetic studies in rats.
Allows co-delivery of dexamethasone sodium phosphate without affecting aprepitant pharmacokinetics.
Documented Applications
Preventing post-operative nausea and vomiting in a subject using the claimed injectable pharmaceutical emulsion.
Prevention and treatment of emesis, including intravenous (IV) treatment scope.
Interested in licensing this patent?